[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"squamous-cell-cancer-of-head-and-neck-scchn\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:squamous-cell-cancer-of-head-and-neck-scchn":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,53,94,122,145,174],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":36,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100575356","phase-1-slv-154-treatment-of-metastatic-solid-tumors-100575356",false,"NCT06771219","SLV-154 Treatment of Metastatic Solid Tumors","A Phase 1 Dose-Escalation Study of SLV-154 in Subjects With Metastatic Solid Tumors","Inclusion Criteria:\n\n1. Men or women (as appropriate for cancer type) of age ≥18 years.\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n3. Histologically or cytologically confirmed diagnosis of solid tumor as documented in medical records with the primary history comprising one of the following:\n\n   1. SCCHN\n   2. NSCLC\n   3. SCLC\n   4. Breast cancer\n   5. Cervical cancer\n   6. Endometrial cancer\n   7. Ovarian cancer\n   8. Urothelial cancer\n   9. Sarcoma\n   10. Thyroid cancer\n4. Presence of metastatic disease that has progressed during or following previous treatment.\n5. Presence of radiographically measurable disease.\n6. Prior receipt of commercially available therapies that are indicated for the subject's cancer and have demonstrated survival benefit for that indication.\n7. Availability of tumor tissue from a fresh tumor biopsy obtained by a core needle, excisional, or incisional biopsy; or punch biopsy (for cutaneous disease); or archival tumor sample from a previous biopsy.\n8. Availability of computed tomography (CT) or magnetic resonance imaging (MRI) of chest, abdomen, and pelvis, and\u002For fluorodeoxyglucose (FDG) positron emission tomography (PET)\u002FCT (if appropriate for tumor type) (with PET from base of the skull to mid-thigh, if performed) within 35 days before study drug administration.\n9. Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, or investigational therapy) for the treatment of cancer ≥1 week before the start of study drug administration.\n10. Adequate hematological profile.\n11. Adequate coagulation profile.\n12. Adequate hepatic profile.\n13. Adequate renal function.\n14. Negative viral serology or adequate therapy for human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) infection.\n15. For female subjects of childbearing potential, a negative serum pregnancy test.\n16. For female subjects of childbearing potential, willingness to use a protocol-recommended method of contraception from the start of the screening period until ≥6 months after the final dose of study therapy.\n17. For male subjects who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use a protocol-recommended method of contraception from the start of study therapy until ≥6 months after the final dose of study therapy and to refrain from sperm donation from the start of study therapy until ≥12 months after administration of the final dose of study therapy.\n18. Willingness and ability of the subject to comply with scheduled visits, the drug administration plan, protocol-specified laboratory tests, other study procedures (including required tumor biopsy\u002Faspirations and\u002For radiographic studies), and study restrictions.\n19. Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.\n\nExclusion Criteria:\n\n1. Malignancy involving the central nervous system unless brain metastases have been previously treated with radiotherapy, have been stable for ≥4 weeks, and do not require corticosteroids.\n2. Presence of another cancer with disease manifestations or therapy that could adversely affect subject safety or longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results.\n3. Uncontrolled ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infection) at the time of start of study therapy.\n4. Significant cardiovascular event or comorbidity.\n5. Significant screening ECG abnormalities.\n6. Pregnancy or breastfeeding.\n7. Major surgery within 4 weeks before the start of study therapy.\n8. Use of a strong inhibitor or inducer of CYP3A4 or CYP1A2.\n9. Use of a drug known to prolong the QT interval within 7 days prior to the start of study drug administration.\n10. Concurrent participation in another therapeutic or imaging clinical trial.\n11. Other conditions likely to interfere with a subject's ability to participate in the study.","ALL","18 Years",{"count":19,"type":20},70,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with metastatic solid tumors.",[26,27,28,29,30,31,32,33,34,35],"Squamous Cell Cancer of Head and Neck (SCCHN)","NSCLC","SCLC","Cervical Cancer Metastatic","Breast Cancer Metastatic","Endometrial Cancer","Ovarian Cancer","Urothelial Cancer","Sarcoma","Thyroid Cancer",[37,38,39],"metastatic solid tumors","metastatic cancer","solid tumor","RECRUITING","2026-06-29",{"date":43,"type":44},"2026-06-30","ACTUAL",{"date":46,"type":44},"2025-05-14",{"date":48,"type":20},"2027-04",{"name":50,"class":51},"Solve Therapeutics","INDUSTRY",10,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":61,"briefSummary":62,"conditions":63,"keywords":74,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":93},"100628371","phase-1-safety-and-feasibility-of-nivolumab-irdye800cw-in-patients-with-head-and-neck-squamous-cell-carcinoma-hnscc-100628371","NCT07460765","Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)","Inclusion Criteria:\n\n* Written informed consent\n* Age ≥ 18 years\n* Participants must have biopsy proven HNSCC or imaging of diagnostic of recurrent cancer or undergoing surgical excision for presumed HNSCC.\n* Adequate hematologic and end-organ function appropriate for surgical resection and anesthesia (within 30 days of infusion).\n* Karnofsky performance status of at least 70% or Eastern Cooperative Oncology Group (ECOG)\u002FZubrod level 0-2.\n* Negative hepatitis B surface antigen (HBsAg) test at screening\n\nExclusion Criteria:\n\n* Patients not planning for SOC surgical resection\n* Active or history of autoimmune disease or immune deficiency, including, but not limited to, HIV, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis with the following exceptions:\n\n  1. Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study.\n  2. Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.\n  3. Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided if all the following conditions are met:\n\n     1. Rash must cover \\\u003C 10% of body surface area\n     2. Disease is well controlled at baseline and requires only low-potency topical corticosteroids\n     3. No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency oral corticosteroids within the previous 12 months\n* History of hepatitis C that has not been treated with curative intent.\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan on active systemic therapy.\n* History of radiation pneumonitis in the radiation field (fibrosis) is permitted.\n* Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina.\n* Severe unresolved infection within 4 weeks prior to initiation of study treatment.\n* Prior allogeneic stem cell or solid organ transplantation.\n* History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins\n* Chronic treatment with systemic immunosuppressive medication in excess of physiologic maintenance doses of corticosteroids (\\>10 mg\u002Fday of prednisone or equivalent) (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-a agents), with the following exceptions:\n\n  1. Patients who received acute, systemic immunosuppressant medication or a dose of systemic immunosuppressant medication are eligible for the study.\n  2. Physiologic corticosteroid replacement therapy at doses ≤ 10 mg\u002Fday of prednisone or equivalent for adrenal or pituitary insufficiency and in the absence of active autoimmune disease is permitted.\n  3. Patients with asthma that requires intermittent use of bronchodilators, inhaled steroids, or steroid injections may participate. Pulse oral steroids of ≤5 days is permitted if \\>30 days from first infusion.\n  4. Patients using topical, ocular, intra-articular, or intranasal steroids (with minimal systemic absorption) may participate.\n  5. Brief courses of corticosteroids for prophylaxis (e.g., contrast dye allergy) or study treatment-related standard premedication is permitted.\n* Pregnant or breastfeeding, or intention of becoming pregnant during study treatment or within 2 months after the final dose of study drug administration.\n* Participants presenting with a baseline QTcF interval \\> than 480 milliseconds.",{"count":60,"type":20},40,[23],"This is a phase 1, open-label, single-center study that plans to enroll 40 participants who will undergo surgical resection as SOC for HNSCC. This trial is designed to evaluate the safety of the safety of fluorescently labeled nivolumab (nivo800) as a molecular imaging agent. The study employs a dose-escalation design across four cohorts of 10 participants each. Participants in Cohorts 1-3 will receive an infusion of nivo followed by an infusion of nivo800 prior to standard-of-care surgical resection. The administration of unlabeled nivo will be administered approximately 2-3 weeks before surgery, followed by an administration of nivo800 administered 1-2 days prior to surgery.",[64,65,66,67,26,68,69,70,71,72,73],"Hnscc","Head and Neck","Squamous Cell Cancer","Squamous Carcinoma","Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)","Squamous Cell Carcinoma Mouth","Squamous Carcinoma Poorly Differentiated","Squamous Cell Cancer of the Head and Neck","Squamous Cell Carcinoma (SCC) of the Oral Cavity","Squamous Cell Carcinoma (SCC)",[75,76,77,78,79,80,81,82,83],"nivo800","neoadjuvant","surgery","head and neck cancer","head and neck","surgical resection","oral cancer","SCC","HNSCC","2026-06-26",{"date":43,"type":44},{"date":87,"type":20},"2026-07",{"date":89,"type":20},"2031-04",{"name":91,"class":92},"Vanderbilt-Ingram Cancer Center","OTHER",1,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":21,"phases":104,"briefSummary":106,"conditions":107,"keywords":108,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":121},"100602610","phase-3-comparing-postoperative-adjuvant-cisplatin-concurrent-chemoradiotherapy-with-adjuvant-radiotherapy-alone-for-intermediate-risk-head-and-neck-squamous-cell-carcinoma-100602610","NCT07125755","Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma","A Prospective, Multicenter, Randomized Controlled Phase 3 Clinical Trial Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma","Inclusion Criteria:\n\nA. The pathological type is head and neck squamous cell carcinoma\n\n* Stages\n\nB. Radical surgery has been performed, and there are intermediary-risk factors (pT3\u002FpT4, pN2\u002FpN3, positive lymph nodes in the cervical IV\u002FV region of oral cancer, nerve invasion, and vascular invasion).\n\nC. No evidence of distant metastasis (M0).\n\nD. Functional status: Karnofsky scale (KPS) \\> 70.\n\nE. Normal bone marrow function:\n\n* white blood cell count \\> 4×109\u002FL\n* hemoglobin \\> 120g\u002FL in males, 110g\u002FL in females\n* platelet count \\> 100×109\u002FL\n\nG. Normal liver function:\n\n* alanine aminotransferase (ALT), aspartate aminotransferase (AST) \\\u003C 1.5 times the upper limit of normal (ULN)\n* alkaline phosphatase (ALP) \\\u003C 2.5×ULN\n* bilirubin \\\u003C ULN.\n\nH. Normal renal function: creatinine clearance \\> 60 ml\u002Fmin.\n\nI. Patients must be informed of the basic contents of this study and sign informed consent.\n\nExclusion Criteria:\n\nA. Age \\>70 years or \\\u003C18 years.\n\nB. Treatment is palliative.\n\nC. Previous chemotherapy (except induction chemotherapy prior to surgery).\n\nD. Previous radiation therapy.\n\nE. Women who are pregnant or breastfeeding\n\nF. Previous history of malignant tumor.\n\nG. With other serious medical conditions that may pose a greater risk or affect compliance with the test. Examples include:\n\n* unstable heart disease that requires treatment\n* kidney disease\n* chronic hepatitis\n* poorly controlled diabetes (fasting blood glucose \\> 1.5×ULN)\n* mental illness.","70 Years",{"count":103,"type":20},386,[105],"PHASE3","The main objective of this trial was to determine the value of concurrent chemoradiotherapy for Intermediate-risk head and neck squamous cell carcinoma",[26],[109,110,111],"Concurrent chemoradiotherapy","Cisplatin","postoperative head and neck squamous cell carcinoma","2026-03-20",{"date":114,"type":44},"2026-03-23",{"date":116,"type":44},"2025-08-15",{"date":118,"type":20},"2031-08-15",{"name":120,"class":92},"Sun Yat-sen University",7,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":21,"phases":132,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":93},"100619766","phase-ii-study-of-daily-adaptive-radiotherapy-for-submandibular-gland-sparing-in-head-and-neck-cancer-100619766","NCT07348887","Phase II Study of Daily Adaptive Radiotherapy for Submandibular Gland-sparing in Head and Neck Cancer","Phase II Randomized Trial of RT-Led Daily Adaptive Radiotherapy for Submandibular Gland-Sparing in Head and Neck Cancer (RTL-DART)","RTL-DART","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histologically proven Squamous Cell carcinoma of head and neck\n* Bilateral neck being treated\n* At least one level 1b not being treated electively and with no target structure, other than elective level II\u002FIII, \\\u003C1cm to spared SMG\n* ECOG PS 0-2\n* Planned for curative (chemo)radiotherapy\n* Able to receive and understand verbal and written information regarding study and able to give written informed consent\n* Be able to lie comfortably on back and to wear immobilization for up to 1 hour\n\nExclusion Criteria:\n\n* As judged by investigator evidence of systemic disease that makes unsuitable for study\n* Pregnancy\n* Underlying salivary dysfunction prior to treatment judged by investigator to affect likelihood of benefit from ART",{"count":131,"type":20},50,[133],"NA","This is a randomized, single centre, single blinded prospective study comparing the standard of care imaging guided radiation therapy and daily adaptive radiotherapy (ART) for submandibular gland-sparing in head and neck cancer",[26],"2026-03-03",{"date":138,"type":44},"2026-03-04",{"date":140,"type":44},"2025-10-15",{"date":142,"type":20},"2029-10-01",{"name":144,"class":92},"University Health Network, Toronto",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":21,"phases":156,"briefSummary":157,"conditions":158,"keywords":161,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":5},"100624131","stereotactic-mri-guided-focused-ultrasound-mesencephalotomy-100624131","NCT07405645","Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy","Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy for Pain Palliation in Head, Neck, & Brachial Cancer","MRg-FUS","Inclusion Criteria:\n\n1. Men and women, between 18 and 85 years, inclusive\n2. Subjects with head, neck, or brachial cancer, including one of the following:\n\n   * Cancer that arises in the head and neck region: nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx (typically squamous cell carcinoma)\n   * Cancer occurring in the nasopharynx, skin, thyroid gland, and eye\n   * Cancer involving the brachial region including brachial plexus, upper lung apex, and Pancoast tumors.\n   * Lymphoma\n   * Sarcoma\n3. Craniofacial, cervical, or brachial pain related to the cancer that meets all of the following criteria:\n\n   * Severe defined by: Worst NPRS score of ≥ 5 out of 10 at current visit and the subject reports having a similar level of pain for at least the past two months.\n   * Pain is medication-refractory to all three tiers of the WHO cancer pain ladder. Thus, adequate trials of at least 3 prescription medications that will include a 'weak' and a 'strong' opioid. An adequate medication trial is defined as a therapeutic dose of each medication without sufficient effect.\n   * Duration of greater than 3 months.\n4. Mesencephalon contralateral to the pain can be targeted by the ExAblate Neuro device. The region of the mesencephalon must be apparent on MRI. Additional MRI sequences including inversion-recovery and DTI may be utilized to refine the target.\n5. Subjects who are able and willing to give consent and able to attend all study visits\n6. Subjects who are able to communicate sensations during the focused ultrasound treatment\n\nExclusion Criteria:\n\n1. Idiopathic trigeminal neuralgia\n2. Trigeminal neuropathic pain from trauma, infection, or iatrogenic\n3. Post-herpetic neuralgia\n4. Headache syndromes like migraine, cluster headache\n5. Temporomandibular joint syndrome\n6. Atypical facial pain or pain related to a somatoform disorder\n7. Subjects deemed poor candidates by a multidisciplinary team of cancer and palliative care clinicians:\n\n   1. Subject deemed by their oncologist to have limited life expectancy for outcome assessment. At least 3 months life expectancy is required to obtain the primary efficacy outcome measure.\n   2. Significant clinician concern about reliability of subject-reported information, such as subject in active process of seeking disability for neuropathic pain\n   3. Subjects exhibiting any behavior(s) consistent with ethanol or substance abuse as defined by the criteria outlined in the DSM-V as manifested by one (or more) of the following occurring within a 12 month period: Recurrent substance use resulting in a failure to fulfill major role obligations at work, school, or home (such as repeated absences or poor work performance related to substance use; substance-related absences, suspensions, or expulsions from school; or neglect of children or household). Recurrent substance use in situations in which it is physically hazardous (such as driving an automobile or operating a machine when impaired by substance use)\n   4. Recurrent substance-related legal problems (such as arrests for substance related disorderly conduct)\n   5. Continued substance use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the substance (for example, arguments with spouse about consequences of intoxication and physical fights).\n8. Subjects with active psychiatric illness will be excluded. For the purpose of this study, active psychiatric illness includes:\n\n   1. Exhibiting current suicide ideation and\u002For a history of suicide attempt within past 2 years\n   2. been hospitalized for the treatment of a psychiatric illness within the past 2 years\n   3. received transcranial magnetic stimulation for depression treatment\n   4. received electroconvulsive therapy for depression\n   5. any presence or history of psychosis\n9. Subjects with unstable cardiac status including:\n\n   1. Unstable angina pectoris on medication\n   2. Subjects with documented myocardial infarction within six months of protocol entry\n   3. Significant congestive heart failure defined with ejection fraction \\\u003C 40\n   4. Subjects with unstable ventricular arrhythmias\n   5. Subjects with atrial arrhythmias that are not rate-controlled\n10. Severe hypertension (diastolic BP \\> 100 on medication)\n11. Subjects with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc.\n12. On medications that increases the bleeding risk, based on the published guidelines which are currently recognized by the American Society of Regional Anesthesia and Pain Medicine, American Academy of Pain Medicine and the North American Neuromodulation Society (Reg Anesth Pain Med 2015;40: 182-212); specifically:\n\n    1. Aspirin or another antiplatelet medication (clopidogrel, prasugrel, ticlopidine, abiciximab) for the last 7 days prior to treatment.\n    2. Oral, subcutaneous or intravenous anticoagulant medications, such as oral vitamin K inhibitors for the last 7 days, non-vitamin K inhibitor oral anticoagulant (dabigatran, apixaban, rivaroxaban) for the last 72 hours.\n    3. Intravenous or subcutaneous heparin-derived compounds for the last 48 hours.\n13. Individuals who are not able or willing to tolerate the required prolonged stationary supine position during treatment (can be up to 4 hours of total table time.)\n14. Subjects participating or have participated in another pain management clinical trial in the last 30 days\n15. Subjects with risk factors for intraoperative or postoperative bleeding from a documented coagulopathy or if their serum coagulation studies (platelet count, PT, PTT, and INR) exceed the institutional laboratory limits.\n16. Subjects with brain tumors or any significant intracranial mass that impedes the acoustic beam. Subjects with cerebral metastasis may be included if the lesion(s) do not affect the FUS treatment.\n17. Any illness that in the investigator's opinion preclude participation in this study\n18. Pregnancy or lactation\n19. Legal incapacity or limited legal capacity\n20. Subjects with a deep brain stimulation implant\n21. Skull density ratio, calculated from the baseline noncontrasted head CT, is less than 0.4\n22. History of hemorrhagic stroke or cerebrovascular event within the past year of treatment exhibiting incomplete resolution\n23. Subjects whose primary pain is other than craniofacial or brachial neuropathic pain.\n24. Patients deemed high risk because of their airway for the procedure as evaluated by anesthesia.","85 Years",{"count":155,"type":20},20,[133],"This phase 1 multi-site study investigates the safety and initial effectiveness of focused ultrasound lesioning of the contralateral mesencephalon for severe, opioid-resistant pain associated with head and neck cancer and brachial cancer.",[159,26,160],"Head Neck Cancer","Cancer Pain",[162,163,164],"cancer pain","mesencephalotomy","focused ultrasound","2026-02-04",{"date":167,"type":44},"2026-02-12",{"date":169,"type":20},"2026-02-15",{"date":171,"type":20},"2029-12-31",{"name":173,"class":92},"University of Virginia",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":21,"phases":183,"briefSummary":184,"conditions":185,"keywords":186,"overallStatus":190,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":200},"100612925","multimodal-prediction-of-response-to-chemoradiotherapy-for-squamous-cell-carcinoma-of-the-head-and-neck-100612925","NCT07259915","Multimodal Prediction of Response to Chemoradiotherapy for Squamous Cell Carcinoma of the Head and Neck","MULTINECK","Inclusion Criteria:\n\n* Patient with squamous cell carcinoma of the oropharynx (cT2-cT4) or squamous cell carcinoma of the oral cavity (cT2-cT4)\n* With lymph node involvement (cN1, cN2, or cN3) (confirmation of lymph node involvement after review of imaging in CCP and without histological confirmation required)\n* Eligible for curative treatment with cisplatin-based chemoradiotherapy alone (100 mg\u002Fm2 every 3 weeks or 40 mg\u002Fm2 weekly)\n* Regardless of p16 status\n* Affiliated with or covered by a social security system\n\nExclusion Criteria:\n\n* Head and neck squamous cell carcinomas in other locations (salivary gland, larynx, hypopharynx, cavum, sinuses)\n* Primary squamous cell carcinoma of the lymph nodes\n* History of radiotherapy to the head and neck region\n* Radiochemotherapy not based on the use of cisplatin\n* Pregnant or breastfeeding women\n* History of invasive cancer in the last 3 years (except for Breslow melanoma less than 1 mm)\n* Contraindication to MRI, CT, or PET\u002FCT\n* Allergy or contraindication to iodine, gadolinium, or 18F-FDG\n* Uncontrolled diabetes (fasting blood glucose greater than 12 mmol\u002Fl)\n* Patients unable to understand the study for any reason or to comply with the trial requirements (language, psychological, geographical issues, etc.)\n* Patients under guardianship or conservatorship\n* Patients deprived of their liberty by judicial or administrative decision\n* Patients undergoing psychiatric care that renders them incapable of giving their consent\n* Patients admitted to a health or social care facility for purposes other than research",{"count":182,"type":20},152,[133],"The goal of the study lies in offering a multimodal analysis of the post-therapeutic response based on both quantitative parameters and radiomics (CT, MRI, and PET imaging), and on tumor biology, in particular the hypersensitive detection of tumor DNA.",[26],[187,188,189],"multimodal approach","CT DNA","Resonance Magnetic Imaging","NOT_YET_RECRUITING","2025-11-21",{"date":193,"type":44},"2025-12-02",{"date":195,"type":20},"2025-12-01",{"date":197,"type":20},"2030-08-01",{"name":199,"class":92},"Centre Henri Becquerel",2]